Close Menu

NEW YORK – Boston-based Ikena Oncology said on Tuesday it has raised $120 million in a Series B funding round, led by investment firm Omega Funds, that it will use to advance its pipeline, specifically its TEAD inhibitor IK-930 and a new preclinical program targeting KRAS signaling.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.